Varun Cruz
Building pharmaceutical infrastructure,
not just another healthtech app.
Varun Cruz founded NEUVIOR to build a vertically integrated pharmaceutical group spanning AI infrastructure, medicines optimisation, supply, labs and pharmacy. In its first months, the group incorporated, secured an Innovate UK Growth Catalyst – New Innovators Award for PHARMORIS®, achieved NHS DSPT Standards Met and began formal IP protection.
“The goal is not to add another dashboard to healthcare. The goal is to build the infrastructure that helps medicines systems decide faster, deploy better and withstand scrutiny.”
Building NEUVIOR®
Start with the system problem
NEUVIOR began with a clear observation: medicines value, supply intelligence and deployment execution were fragmented across organisations and datasets.
Instead of building a single-point solution, Varun designed the business as a group structure capable of connecting research, intelligence, supply and pharmacy into one long-term operating model.
Build around PHARMORIS®
PHARMORIS was shaped as a medicines value operating system for health systems - not a generic AI dashboard and not a full eCTD product. Its role is to help teams discover, justify and deploy high-value medicines opportunities.
That clarity matters to NHS buyers, investors and journalists because it defines what the product does today and what remains a future adjacency.
"“Most tools show what happened. PHARMORIS is designed to show what to do next.”"
Move fast with discipline
Within 39 days of incorporation, the company secured its first Innovate UK win for PHARMORIS.
The early pace came from clear positioning, disciplined product architecture and a willingness to use precise language about what is live, what is being piloted and what is still under development.
Early milestones
From incorporation to public validation - building credibility through execution, governance and product clarity.
NEUVIOR® incorporated
Founded NEUVIOR Pharmaceuticals Ltd in Glasgow on 4 August 2025 with a vertically integrated pharmaceutical group model.
Innovate UK Growth Catalyst – New Innovators Award
Awarded for PHARMORIS™ - Generics Optimisation Platform for NHS and Global Health, 39 days from incorporation.
NHS DSPT Standards Met
Published for the 2025-26 cycle, strengthening readiness for NHS-facing discussions and pilots.
PHARMORIS® trade mark published
UK00004301201 published by the Intellectual Property Office, formalising protection of the platform’s commercial identity.
Patent filing initiated
IPO UK patent filing completed for core architecture, with international PCT protection planned for 2026.
Guiding principles
The beliefs that shape product language, operating choices and the standards NEUVIOR holds itself to.
Strategic clarity
Every decision starts with category definition, buyer need and execution pathway. Clarity removes noise and helps the group compound.
"“If the product story is vague, the business model is vague.”"
Disciplined execution
Early milestones came from structuring work around evidence, roles and sequence - not from overclaiming.
"“Speed matters when the foundations are correct.”"
Unwavering integrity
That standard applies to product language, regulatory posture, public statements and every external claim the business makes.
"“Trust comes from saying what is true, what is proven and what still needs to be built.”"
Innovation with purpose
NEUVIOR builds infrastructure that serves pharmacy, providers, commissioners and patients - not novelty for its own sake.
"“Technology only matters if it improves medicines value, resilience or patient care.”"
Milestones & recognition
From incorporation to Growth Catalyst – New Innovators validation for PHARMORIS®.
Published as Standards Met for the 2025-26 cycle as part of the group’s NHS readiness posture.
Formal trade mark publication supporting protection of the platform and its commercial identity.
Core architecture filed in the UK with international PCT protection planned.
Thought leadership
Themes and perspectives shaping Varun Cruz’s public commentary on medicines infrastructure, AI and regulated execution.
Why medicines infrastructure matters now
How PHARMORIS moves from dashboard-heavy analytics to action across commissioning and provider workflows.
Connect with Varun
For investor relations, press enquiries, partnership opportunities or speaking requests.
Investor Relations
Discuss the group model, PHARMORIS commercial strategy and long-term infrastructure roadmap.
Press & Media
Request interviews, background briefings, founder commentary or approved corporate materials.